Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He'll score points with the street if he can do something about that burn rate.
Some good (hopeful) reading about our new CEO:
http://www.sec.gov/Archives/edgar/data/1340744/000129993308002714/0001299933-08-002714-index.htm
The firs paragraph of David Pendergast's offer letter is especially encouaring (link to exhibit below):
http://www.sec.gov/Archives/edgar/data/1340744/000129993308002714/exhibit1.htm
Altus Pharmaceuticals Appoints Georges Gemayel Chief Executive Officer and Member of Board of Directors
Thursday May 22, 8:32 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU - News), today announced the appointment of Georges Gemayel, Ph.D. as Chief Executive Officer and a member of the Company’s Board of Directors, effective June 2, 2008. Dr. Gemayel joins Altus Pharmaceuticals from Genzyme Corporation where he was Executive Vice President and a company officer. Dr. David Pendergast, who was serving as Executive Chairman, will continue as Chairman of the Altus Board.
“Georges is the ideal person to lead Altus. He is a proven leader with extensive industry experience and skills spanning operations management, clinical development, regulatory strategy, corporate alliance management, product launch and marketing,” said Dr. David Pendergast, Chairman of Altus’ Board of Directors. “Throughout his tenures at Genzyme and Roche, Georges has demonstrated exceptional leadership and vision as well as the ability to deliver results by driving programs through clinical and operational challenges. He has a track record of successfully building commercial teams and working with collaborators to maximize product opportunities, and we are delighted that he will be guiding the Company forward.”
Source: Altus Pharmaceuticals Inc.
· Georges Gemayel, Ph.D., newly appointed Chief Executive Officer of Altus Pharmaceuticals (Business Wire: Photo). View Multimedia Gallery
“I am honored to join Altus at this critical time in the Company’s history. I believe the Company’s technology, pipeline of protein therapeutics and enzyme replacement therapies hold tremendous clinical potential and value,” commented Dr. Gemayel. “I look forward to working with the entire Altus team on achieving our near-term goals, driving Trizytek™ toward commercialization and building long-term value for our shareholders.”
Dr. Gemayel joined Genzyme in 2003. He was responsible for the company’s therapeutics, transplant, renal and biosurgery businesses. Before he joined Genzyme, Dr. Gemayel worked for the health care company Hoffman-LaRoche for 16 years. There he served as vice president of the U.S. Specialty Care Business with responsibilities for oncology, transplantation, hepatitis, HIV and dermatology. He also was the general manager of Hoffman-LaRoche Portugal. Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut and earned a Ph.D. in pharmacology at Paris-Sud University.
In connection with joining the Company, Dr. Gemayel will be granted stock options to purchase up to 900,000 shares of common stock of Altus Pharmaceuticals at an exercise price per share equal to the closing price of the Company’s common stock on June 2, 2008, the first day of Dr. Gemayel’s employment with the Company. The total grant will be comprised of options to purchase 560,000 shares under the Company’s stock option plan and an inducement grant of a non-qualified option to purchase 340,000 shares. The inducement award was granted in reliance upon NASDAQ Marketplace Rule 4350 (i)(1)(A)(iv). Both the option grant under the stock option plan and the inducement grant will have a ten-year term. The first 25 percent of all such options will vest on the first anniversary of Dr. Gemayel’s employment with the Company, and the remaining 75 percent will vest quarterly over the following three years, subject to continued employment or service through each relevant vesting date. The inducement award will be granted on substantially identical terms and conditions as those contained in the Company’s stock option plan.
About Altus Pharmaceuticals Inc.
Altus Pharmaceuticals, headquartered in Cambridge, MA, is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com. Trizytek™ is a trademark of Altus Pharmaceuticals.
that is a good point. haha.
Well so much for the market thinking a buy out is in the works. As long as 135 (Trizytek) doesn't have any (further) setbacks and we got a signal (measuring oxalate in urine) for 237 then I would prefer no buyout just good permanent management!
Altus Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
http://seekingalpha.com/article/76162-altus-pharmaceuticals-inc-q1-2008-earnings-call-transcript?source=yahoo
I replied on the Biotech values board #msg-29372606
pharmawire article
12:07 Altus Pharmaceuticals retains Morgan Stanley to review strategic options - sources
Story Altus Pharmaceuticals has retained Morgan Stanley to review strategic options, it is understood. The listed biopharmaceutical, based in Cambridge, Massachusetts, is said to have only just appointed the US investment bank.
A spokesperson for the company declined to comment.
One source familiar situation said that Morgan Stanley was working with the drug developer but did not divulge any further information. A second source said that they had seen an information memorandum on the company.
Other sources said that were not surprised by the news, with one US business development consultant noting that Altus had been "shopping its products at the same time". The company had a setback last December when Genentech sold back the development and commercial rights to ALTU-238, a growth hormone drug that the two companies had partnered on. At the time, the company believed it could find another partner for the drug.
In February, chief executive Sheldon Berkle resigned and was replaced by chairman Dr David Pendergast, who is still assuming executive duties until a replacement is found. Pendergast was part of the management team at Transkaryotic Therapies when it was sold to Shire in 2005, and subsequently headed up the UK-listed company's genetic therapies unit. Altus has been previously reported as a possible target for Shire.
Altus is developing a series of products to treat gastrointestinal and metabolic disorders. Its lead compound is Trizytek, a porcine-free enzyme in Phase III development for pancreatic insufficiency.
Altus has a market cap of USD 123m.
Altus Pharmaceuticals Reports First Quarter Results
Wednesday May 7, 8:27 am ET
- - Trizytek(TM) Efficacy Trial Enrollment Complete - -
- - 175 Patients Enrolled in Trizytek Safety Study - -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU - News), a biopharmaceutical company focused on oral and injectable protein therapeutics for gastrointestinal and metabolic disorders, today reported financial results for the quarter ended March 31, 2008.
First Quarter 2008 Results
For the first quarter of 2008, the Company reported a net loss attributable to common stockholders of $24.6 million, or $0.80 per share, compared to a net loss attributable to common stockholders of $15.8 million, or $0.67 per share, in the first quarter of 2007. Revenues were $2.6 million in the first quarter of 2008 compared to $827,000 the first quarter of 2007. The increase in first quarter revenue is primarily attributable to revenue associated with the Company’s agreement with Cystic Fibrosis Foundation Therapeutics, Inc. for the development of TrizytekTM [porcine-free enzymes] (formerly ALTU-135) as well as additional revenue from Genentech, Inc. in the first quarter of 2008. Cash, cash equivalents and marketable securities at March 31, 2008 were $118.0 million.
Research and development expenses totaled $21.6 million in the first quarter of 2008 compared to $12.9 million in the first quarter of 2007. The increase in R&D expenses is primarily due to an increase in development costs relating to conducting the Trizytek Phase 3 safety and efficacy trials.
General and administrative expenses were $5.8 million in the first quarter of 2008 compared to $4.6 million in the first quarter of 2007. The increase in G&A expenses was primarily driven by a one-time charge of $600,000 associated with a separation agreement with Altus’ former chief executive officer as well as increased recruiting costs related to the search for a new CEO.
“Altus is advancing a robust product pipeline of crystallized protein therapies. We are committed to bring these new therapies to patients with our initial focus on driving Trizytek to commercialization,” stated Dr. David Pendergast, Executive Chairman of Altus Pharmaceuticals. “We are pleased to report that the patient enrollment phase of the Trizytek efficacy trial is complete and we continue to be confident that we will report top-line efficacy results in the third quarter. The safety study has 175 patients currently enrolled, which is sufficient for the one-year safety data on the required 100 patients to be included in our NDA filing in the first half of 2009.”
Dr. Pendergast continued, “We look forward to initiating and completing this summer the ALTU-238 Phase 1c study, which we expect will include 36 patients. This trial is designed to confirm that the ALTU-238 material, produced at the current increased manufacturing scale, performs similar to the material used in previous studies.”
Dr. Pendergast concluded, “The Altus team is very focused on continuing to move our clinical programs forward. We are well positioned for success with a pipeline consisting of three products in human clinical development and two products that are in preclinical testing. We believe the next several months will be a very exciting time as we plan to achieve several key milestones: releasing ALTU-237 Phase 1 data in the second quarter; reinitiating the ALTU-238 development program in the third quarter; and reporting top-line Trizytek Phase 3 efficacy results in the third quarter.”
Conference Call Access Information
The Company will host a conference call to discuss the results at 11:00 a.m. ET on May 7. The call may be joined via telephone by dialing (877) 548-7911 or 719-325-4881 (for international participants) at least 5 minutes prior to the start of the call. The conference confirmation code is: 7245147. For 72 hours following the call, an audio replay can be accessed by dialing (719) 457-0820 or (888) 203-1112 and using the conference confirmation code 7245147.
A live audio webcast of the call will also be available on the "Investor Relations" section of the Company's website, www.altus.com. An archived audio webcast will be available on the Altus website approximately two hours after the event and will be archived for 30 days.
http://biz.yahoo.com/bw/080507/20080507005414.html?.v=1
FORM S-8
the S-8 is holding back ALTU
ALTUS PHARMACEUTICALS INC.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000950135%2D08%2D001706%2Etxt&FilePath=%5C2008%5C03%5C11%5C&CoName=ALTUS+PHARMACEUTICALS+INC%2E&FormType=S%2D8&RcvdDate=3%2F11%2F2008&pdf=
Altus Pharmaceuticals Swings To Profit In Q4; Provides Milestones For Various Programs - Quick Facts
(RTTNews) - Altus Pharmaceuticals Inc. (ALTU) on Tuesday reported fourth-quarter net income of $5.47 million from last year's net loss of $14.38 million a year ago. Net income attributable to common stockholders was $5.41 million, compared to net loss of $14.48 million last year. Net income attributable to common stockholders per share was $0.16, compared to net loss per share of $0.63.
Total revenue for the quarter soared to $26.77 million from $1.14 million in the comparable quarter of last year, primarily due to its former ALTU-238 collaboration agreement with Genentech Inc. (DNA), which was terminated effective December 31, 2007. Included in the fourth quarter revenue was $25.1 million associated with the ALTU-238 agreement.
Looking ahead, the firm expects net cash used in operating activities to be between $85 million and $95 million in 2008. This is based on its current operating plans, expected timing and cost of the Trizytek Phase 3 efficacy and safety trials, the ALTU-238 Phase 1c trial, and the ALTU-237 Phase 1 clinical trial and other product development programs.
Among other programs, Altus noted that the Trizytek NDA submission remains on track for first-half of 2009. It reiterated its plans to conduct the Phase 1c trial for ALTU-238, and also plans to report data from the Phase 1 trial of ALTU-237 in hyperoxaluria during the second quarter of 2008.
Thursday's Health Winners & Losers(ALTU)
http://www.thestreet.com/_yahoo/newsanalysis/winnershealth/10408784.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
Altus Shares Rise on Partnership Outlook
Thursday March 20, 7:48 pm ET
Altus Shares Rise As Jefferies Reaffirms 'Buy' Rating on Outlook for Program Partnerships
NEW YORK (AP) -- Shares of Altus Pharmaceuticals rose Thursday as Jefferies & Co. reaffirmed a "Buy" rating on the stock, citing the potential for a partnerships on several developing drugs.
The stock gained 34 cents, or 7.4 percent, to close at $4.95. Shares have traded between $4.35 and $16.13 in the last 52 weeks.
Analyst Eun Yang maintained a $16 price target while citing the partnership potential for Altus' Trizytek pancreatic insufficiency treatment in patients with cystic fibrosis and the growth hormone ALTU-238. Pancreatic insufficiency is an inability to properly digest food.
She said near-term financing risks linger for the company, but the stock might be worth the long-term risk.
Altus is expected to ask the Food and Drug Administration for Trizytek approval in the first half of 2009.
I posted this on the BMRN board but as a lot of it pertains to Altus I thought I would cross post it here too:
#msg-26678891
Congratulations fear I see you are no longer moderator so I guess it hit your target and your out? I've lightened my position too but still really like the company.
I've been thinking more and more about the cash they have and JJ's comments in the past year and I get the sense they may do a descent sized deal yet. Why? No reason in particular but it strikes me as an opportunistic time in biotech land as many are not much above cash and/or are cash strapped. The two deals they did were very minor in my book and I think JJ wants a more near-to-market product.
I could see a deal like the following (and I don't necessarily want it to happen as I am down a fair amount on the stock just pose it as an example)...
Take Altus Pharmaceuticals. Stock is about 6 and has 30 million shares and say about 140 million in cash/securities (this is all back-of-the-hand so give me some flexibility I know they have some debts but they also have NOL's). So basically the market is valuing the technology at 40 million. They have 3 products in human testing and several more preclinical. One product in preclinical would be a direct competitor to PEG-PAL (a.k.a. treatment for all PKU patients especially non-Kuvan responders). Their most advanced product Trizytek (ALTU-135) is a pancreatic enzyme replacement therapy used primarily by cystic fibrosis patients and interestingly Biomarin just licensed a cf product. I also think Biomarin would have strong interest ALTU-237 (hyperoxaluria).
The CEO recently left and former TKT CEO/COO replaced him. If Altus were to be broken up (aside from the technology, ALTU-238 is their other key asset) I am sure the three products I mentioned above would be worth > 100 million to BioMarin and yet the market is saying you can have them and more for 40 million.
I am familiar with both companies so this example comes readily but there are probably many other late stage drugs available for licensing by companies that don't have the cash/resources to commercialize them.
Good thing I waited until more news to buy in. Stock takes a 50% haircut on Genentech abandoning plans to develop crystallized GH.
http://www.fool.com/investing/high-growth/2007/10/02/this-just-in-upgrades-and-downgrades.aspx
Always looking for news on my IHUB stocks, couldn't find much so I am posting this little link for ALTU.
I try not to let the IHUB go much past a month without a post, this one was really a stretch.
yep, this is a stock that nearly touched 20 in january.
Improving Chaikin Money Flow (ALTU)
Parabolic SAR Buy Signals (ALTU)
Interesting, it looks like their following in the footsteps of the their lead program- the digestable crystalline formulation for pancreatic insufficiency.
Altus Pharmaceuticals' ALTU-237 Enters Phase I Clinical Trial for the Treatment of Hyperoxalurias and the Potential Prevention of Kidney Stone Formation
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) today announced that it has initiated a Phase I clinical trial of ALTU-237, an orally-delivered crystalline formulation of an oxalate-degrading enzyme that is being developed for the treatment of hyperoxalurias and the possible prevention of recurrent kidney stones in individuals with a high risk or history of kidney stones. ALTU-237 has the potential to address these conditions, for which there are limited effective pharmacological treatments.
The ALTU-237 Phase I clinical trial is a single-center, double-blind, placebo-controlled, dose escalating study evaluating the safety and tolerability of ALTU-237 in normal, healthy adults. The study plans to enroll 64 normal, healthy adults that will be randomized into several cohorts. A secondary objective of the trial is to determine the clinical activity of escalating dose levels of ALTU-237, as measured by changes in urinary oxalate levels in normal healthy adults on a controlled, high oxalate diet and to identify a dose of ALTU-237 for future studies.
“This clinical trial is another important step in evaluating the potential of ALTU-237 as a treatment for hyperoxalurias and the prevention of recurrent kidney stones,” stated Sheldon Berkle, President and CEO of Altus Pharmaceuticals. “The broad range of doses should provide valuable information for future trial design. If the Phase I trial results demonstrate that ALTU-237 is safe in humans, we expect to conduct additional clinical trials to investigate the potential activity of ALTU-237 in different hyperoxaluria-related indications.”
About Hyperoxaluria
Hyperoxaluria is a disease characterized by excessively high levels of oxalate in the urine, which can be a precursor to forming kidney stones. Hyperoxaluria can be caused by either excessive absorption of dietary oxalate (enteric hyperoxaluria) or increased endogenous production of oxalate (primary hyperoxaluria). When untreated, primary hyperoxaluria could lead to recurrent kidney stones and could contribute to renal failure. Ultimately, patients suffering from severe primary hyperoxaluria experience calcium deposits in their organs, which, if left untreated, could lead to death.
Altus is definitely a company to watch, but Im not buying in until they get a little closer to news. However, I'm intrigued by their technology platform and I like the pancreatic insufficiency indication.
Thanks for starting the board up, I will be bookmarking it.
Parabolic SAR Buy Signals (ALTU) from nightly stockcharts.com scan
Altus Pharmaceuticals Reports Second Quarter 2007 Results
Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, today reported financial results for the quarter ended June 30, 2007.
For the second quarter of 2007, the Company reported a net loss attributable to common stockholders of $30.5 million, or $1.06 per share, compared to a net loss attributable to common stockholders of $15.0 million, or $0.68 per share, in the second quarter of 2006. Total revenues were $1.5 million in the second quarter of 2007 compared to $4.4 million in the second quarter of 2006. Second quarter revenue decreased over the comparable quarter in 2006 primarily due to the termination of the Company’s agreement with Dr. Falk Pharma in 2007.
Research and development expenses totaled $17.9 million in the second quarter of 2007 compared to $17.3 million in the second quarter of 2006. Second quarter 2007 R&D spending reflects continued clinical and manufacturing costs associated with ALTU-135, investments in ALTU-238 clinical manufacturing capacity, outsourced third-party and internal costs related to the ALTU-237 IND submission and development spending on Altus’ early stage pre-clinical projects. General, sales and administrative expenses were $4.1 million in the second quarter of 2007 compared to $3.3 million in the second quarter of 2006. This increase is primarily due to increases in personnel, legal, consulting and professional service fees.
The total expenses for the second quarter were $33.6 million compared to $20.6 million in the second quarter of 2006. The increase in 2007 total expenses was primarily attributable to a charge of $11.5 million associated with the termination of the Dr. Falk Pharma agreement and reacquisition of European marketing rights to ALTU-135.
2007 Financial Guidance
Cash, cash equivalents and short-term marketable securities balances at June 30, 2007 totaled $178 million. Based on current operating plans and the expected timing of product development programs, Altus believes that net cash used in operating activities will be between $45 million and $55 million in 2007. Previously, Altus had provided guidance that net cash used in operating activities would be between $55 million and $65 million in 2007. Altus believes its current cash position will fund operations through the first half of 2009.
Second Quarter 2007 Accomplishments include:
* Started Phase III ALTU-135 clinical trials
* Submitted IND to study ALTU-237 for the treatment of hyperoxalurias and the potential prevention of kidney stone formation
* Reacquired European development and commercialization rights to ALTU-135
“During the second quarter, Altus delivered on two corporate milestones, including the initiation of our ALTU-135 Phase III clinical trials and our submission of an IND for ALTU-237,” stated Sheldon Berkle, President and Chief Executive Officer of Altus Pharmaceuticals. “Each individual milestone alone is a significant accomplishment for any biotech company, which only further demonstrates why we are very proud of the Altus team for achieving both objectives during the quarter.”
On May 9, 2007, the Company announced the start of its Phase III clinical trials to evaluate the efficacy and safety of ALTU-135, an oral enzyme replacement therapy for cystic fibrosis patients with pancreatic insufficiency. Altus’ consistent and pure enzyme combination, ALTU-135, is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. The DIGEST trials (Determining the efficacy and safety of an Innovative GastrointESTinal enzyme complex) consist of a Phase III efficacy trial and a Phase III safety trial.
Altus plans to recruit approximately 300 patients from more than 50 sites worldwide for the two trials, making this Phase III program the largest ever conducted to evaluate the efficacy and safety of pancreatic enzyme replacement therapy in cystic fibrosis patients. ALTU-135 has been tested in more than 160 cystic fibrosis patients including a 129 patient Phase II trial. The DIGEST trials are seeking patient participation. For information please visit www.altus.com/digesttrials.cfm. The DIGEST efficacy trial, which is testing a one capsule per meal dosing regimen, is studying the fat absorption in cystic fibrosis patients with exocrine pancreatic insufficiency through the measurement of the coefficient of fat absorption (CFA). In parallel, Altus is conducting a long-term safety study that will evaluate ALTU-135 over one year of open-label treatment.
Commenting on the DIGEST trials, Berkle said, “The DIGEST trials continue to enroll clinical sites and patients. As we previously stated, we expect to report top-line efficacy data from this trial in the second quarter of 2008.”
Also during the second quarter, Altus announced that it reacquired from Dr. Falk Pharma the development and commercialization rights to ALTU-135 and ended the development and commercialization collaboration in Europe and countries of the former Soviet Union, Israel and Egypt. Under the agreement, Altus regains control of all of the assets created in the collaboration. In exchange, Altus will pay Dr. Falk Pharma €12.0 million over three years.
Berkle continued, “We believe reporting Phase III top-line efficacy data can be a significant value creating event for ALTU-135 and Altus. To maximize the value of our ALTU-135 assets, we continue to evaluate our strategic options outside of North America.”
Conference Call Access Information
The Company will host a conference call to discuss the second quarter results at 11:00 a.m. ET on August 8. The call may be joined via telephone by dialing (800) 817-4887 or (913) 981-4913 (for international participants) at least 5 minutes prior to the start of the call. The conference confirmation code is: 6945814. For 72 hours following the call, an audio replay can be accessed by dialing (719) 457-0820 or (888) 203-1112 and using the conference confirmation code 6945814.
About Altus Pharmaceuticals Inc.
Altus Pharmaceuticals is a company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com.
Safe Harbor Statement
Certain statements in this news release concerning Altus’ business are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, those relating to our 2007 financial guidance, the anticipated net cash requirements to be used to fund on-going development programs and operations, and the plans for and the scientific robustness of our ALTU-135 clinical development program. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Altus might make or by known or unknown risks and uncertainties, including, but not limited to uncertainties as to the future success or timing of ongoing and planned clinical trials, inherent uncertainties in the timing of patient enrollment in our clinical trials, the continued development of our manufacturing processes in parallel with our clinical programs, the performance and development plans of our third party collaborators, and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Altus’ reports to the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended June 30, 2007. However, Altus undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.
ALTUS PHARMACEUTICALS INC. (ALTU)
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
Contract revenue $ 1,508 $ 4,410 $ 2,335 $ 5,922
Costs and expenses:
Research and development 17,940 17,314 30,799 27,103
General, sales and administrative 4,135 3,330 8,716 6,437
Reacquisition of European marketing rights from Dr. Falk 11,493 - 11,493 -
Total costs and expenses 33,568 20,644 51,008 33,540
Loss from operations (32,060) (16,234) (48,673) (27,618)
Other income (expense):
Interest income 1,937 1,495 2,946 2,540
Interest expense (290) (177) (453) (368)
Foreign currency loss (23) - (23) -
Total other income (expense) —net 1,624 1,318 2,470 2,172
Net loss (30,436) (14,916) (46,203) (25,446)
Preferred stock dividends and accretion (56) (100) (113) (1,086)
Net loss attributable to common stockholders $ (30,492) $ (15,016) $ (46,316) $ (26,532)
Net loss attributable to common stockholders per share - basic and diluted
$ (1.06) $ (0.68) $ (1.77) $ (1.42)
Weighted average shares outstanding - basic and diluted 28,844 22,200 26,172 18,693
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)
June 30, December 31,
2007 2006
Cash, cash equivalents and marketable securities $ 178,066 $ 85,914
Prepaid expenses and other current assets 2,341 2,576
Property and equipment, net 6,393 6,717
Other assets, net 1,029 1,254
Total assets $ 187,829 $ 96,461
Current liabilities $ 25,083 $ 17,183
Noncurrent liabilities 23,322 3,575
Redeemable preferred stock 6,394 6,281
Total stockholders' equity 133,030 69,422
Total liabilities, redeemable preferred stock and stockholders' equity
$ 187,829 $ 96,461
Altus Pharmaceuticals
John A. Jordan, 617-299-2852
Senior Director, Corporate Communications
Source: Business Wire (August 8, 2007 - 6:57 AM EST)
News by QuoteMedia
www
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
125
|
Created
|
08/09/07
|
Type
|
Free
|
Moderators |
The CH7 may be filed very soon with the liquidation value 0.01 per share at most!
http://finance.yahoo.com/q/ks?s=ALTU
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |